BioScience Health Innovations, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BioScience Health Innovations, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.69M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.84M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $597.6K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $69.3K | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | $0 | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | $0 | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | $0 | Nov 26, 2021 |
| FY2020 | Aug 31, 2019 | $0 | Nov 25, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.24M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.31M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $484.4K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $59.6K | Mar 29, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $642.1K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $87.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($251.5K) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($170.5K) | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | ($83.2K) | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | ($25.6K) | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | ($7.7K) | Nov 26, 2021 |
| FY2020 | Aug 31, 2019 | ($900) | Nov 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $719.1K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $87.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($251.5K) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($170.5K) | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | ($91.9K) | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | ($25.6K) | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | ($7.7K) | Nov 26, 2021 |
| FY2020 | Aug 31, 2019 | ($900) | Nov 25, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $161.4K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $25.9K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 13, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.21M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.15M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $706.3K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $151.3K | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | $91.9K | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | $25.6K | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | $7.7K | Nov 26, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $172.2K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $23.2K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($307.8K) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($182.8K) | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | ($85.8K) | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | ($29.4K) | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | ($7.7K) | Nov 26, 2021 |
| FY2020 | Aug 31, 2019 | ($2.8K) | Nov 25, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.71M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $873.8K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $93.4K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $31.6K | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | $16.3K | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | $6.3K | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | $20.6K | Nov 26, 2021 |
| FY2020 | Aug 31, 2019 | $1.9K | Nov 25, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $229.9K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $38.5K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $100.1K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $48.8K | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | $1.9K | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | $19.1K | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | $7.8K | Nov 26, 2021 |
| FY2020 | Aug 31, 2019 | $0 | Nov 25, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $835.2K | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | ($6.8K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | ($17.2K) | Mar 13, 2025 |
| FY2022 | Aug 31, 2022 | $14.4K | Nov 1, 2022 |
| FY2023 | Dec 31, 2021 | ($1.0K) | Mar 29, 2024 |
| FY2022 | Aug 31, 2021 | ($12.8K) | Nov 1, 2022 |
| FY2022 | Aug 31, 2020 | $12.8K | Nov 1, 2022 |
| FY2021 | Aug 31, 2019 | $1.9K | Nov 26, 2021 |
| FY2020 | Jul 7, 2019 | $0 | Nov 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $301.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($341.1K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($428.1K) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($176.6K) | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | ($117.4K) | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | ($34.2K) | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | ($8.6K) | Nov 26, 2021 |
| FY2020 | Aug 31, 2019 | ($900) | Nov 25, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $661.9K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $662.5K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $19.2K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $11.6K | Mar 29, 2024 |
| FY2021 | Aug 31, 2021 | $2.0K | Nov 26, 2021 |
| FY2021 | Aug 31, 2020 | $20.6K | Nov 26, 2021 |
| FY2021 | Aug 31, 2019 | $0 | Nov 26, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.98M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 10.98M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 40.90M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 5.46M | Mar 29, 2024 |
| FY2022 | Aug 31, 2022 | 5.46M | Nov 1, 2022 |
| FY2022 | Aug 31, 2021 | 5.46M | Nov 1, 2022 |
| FY2021 | Aug 31, 2020 | 5.46M | Nov 26, 2021 |
| FY2020 | Aug 31, 2019 | 2.80M | Nov 25, 2020 |